Nektar Therapeutics (NKTR) said Monday the US Food and Drug Administration has granted fast-track designation to its experimental drug, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis in certain adults and pediatric patients aged 12 and older.
The company said it plans to announce data from the induction period of its phase 2b study in the second quarter of this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.